Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on NewAmsterdam Pharma Company, retaining the price target of $52.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Pantginis has given his Buy rating due to a combination of factors tied to NewAmsterdam’s advancing clinical and financial position. He highlights strong momentum behind the late-stage PREVAIL cardiovascular outcomes trial, supported by encouraging early major adverse cardiovascular event trends, robust study design, and a carefully selected patient population that together support confidence in a positive readout.
In addition, he points to the broader Phase 3 program, including RUBENS and REMBRANDT, which reinforces obicetrapib’s potential beyond LDL-C reduction and into wider metabolic and cardiovascular risk settings, with further upside from possible combination studies. Pantginis also underscores the company’s solid cash balance, expected to carry operations through the pivotal PREVAIL data and an anticipated U.S. launch, along with potential European approvals by late 2026, all of which support a favorable risk‑reward profile for NAMS shares.